奥门丁-1通过GRK4/AT1R下调调节,通过ROS/c-Myc通路调节,减轻对盐敏感的高血压
Ruifang Hua1, Zhaohai Su2, Xiang Lin3
1Department of Nephrology, Ganzhou Hospital of Guangdong Provincial People's Hospital, Ganzhou Municipal Hospital, Ganzhou 341009 Jiangxi, China.
Biochemical pharmacology
|October 29, 2025
概括
奥门丁-1过度表达会降低血压,并保护盐敏感高血压患者的脏. 它通过抑制ROS/c-Myc/GRK4/AT1R通路而起作用,提供了一个潜在的治疗标.
科学领域:
- 心血管研究研究心血管研究
- 腎臟病學 (nephrology) 是一種醫學.
- 内分泌学 在内分泌学.
背景情况:
- 与高摄入量相关的高血压是一个全球性的健康问题.
- 奥门丁-1是一种阿迪波金,具有抗炎和抗氧化作用,但其对盐敏感高血压的影响尚不清楚.
研究的目的:
- 为了研究奥门丁-1. 1的降血压和脏保护作用.
- 在脱氧皮质乙酸盐 (DOCA) -盐高血压的老鼠模型中阐明潜在的分子机制.
主要方法:
- 使用DOCA盐的老鼠模型来诱导高血压.
- 评估了欧门丁-1过度表达对血压,功能标志物 (血清肌素,BUN),纤维化和病学的影响.
- 在组织中研究了血管新素II型1受体 (AT1R) 和G蛋白结合受体激酶4 (GRK4) 的表达.
- 探索了活性氧物种 (ROS) /c-Myc信号通路在调解omentin-1的作用中的作用.
主要成果:
- 在高血压大鼠中,欧门丁-1的过度表达显著降低了血压,并改善了功能.
- 奥门丁-1 降低了纤维化和改善了脏组织病理学.
- 奥门丁-1通过ROS/c-Myc通路降低了脏AT1R和GRK4的表达.
- 过度表达GRK4抵消了奥门丁-1的有益作用,证实了其作为调解者的作用.
结论:
- 奥门丁-1在对盐敏感高血压患者中表现出显著的抗高血压和保护作用.
- 该机制包括抑制ROS/c-Myc/GRK4/AT1R信号轴.
- 奥门丁-1代表了对管理盐敏感高血压和相关损伤的有前途的治疗标.
更多相关视频
相关概念视频
Antihypertensive Drugs: Angiotensin II Receptor Blockers
2.4K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.4K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
915
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
915
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
2.3K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.3K
Antihypertensive Drugs: Direct Renin Inhibitors
1.3K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.3K
Antihypertensive Drugs: Action of β1 Blockers
1.9K
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
1.9K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
433
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
433


